Shigella-attributed diarrhoea is common among young children in LMICs, with its escalating antimicrobial resistance posing a serious threat to global public health. The leading quadrivalent vaccine candidates cover the majority of Shigella serotypes identified in this study. These data affirm both the need for Shigella vaccines and readiness of EFGH sites to conduct rigorous vaccine trials.
The Lancet Global Health published a clinical update in Infectious Disease on 11 Mar 2026. The item focuses on The incidence and antimicrobial resistance of Shigella-attributable diarrhoea in young children in low-income and middle-income countries from the multicountry Enterics for Global Health (EFGH) Shigella Surveillance Study: a prospective, facility-based hybrid surveillance study. Open the detail page to review the full original feed content.